 | Forbes - Business |
| |
Current Headlines | Most Read | Archives |
|
| |
 |
Sponsor's Content: Hold 'Em Accountable (07 July 01:17) |
| Garner more profits. Instill accountability in your work force. |
| |
|
The Great Drug Debate (03 July 03:43) |
| An FDA meeting on diabetes provides a window into controversies that are shaking the drug industry. |
| |
|
The Statin Showdown (30 June 04:24) |
| A complex scientific debate underpins the controversy over cholesterol drugs. |
| |
|
Sponsor's Content: Power to Your People, Money in Your Pocket (30 June 01:21) |
| Companies that enable employees to make decisions are three times more successful than competitors. Find out why. |
| |
|
Analyst Says Bristol-Myers A Buyout Target (27 June 09:18) |
| Could a take-out be in the pharma company's future? If so Pfizer is the ideal purchaser. |
| |
|
Glaxo Pays For Chantix Woes (27 June 02:35) |
| The Pharma company fights to separate itself from the competition's bad rep. |
| |
|
Broken Biovail May Be Irreparable (26 June 04:00) |
| If ex-head Melnyk loses court challenge to board, he'll start a new company. |
| |
|
Biovail Founder Wants His Way (26 June 03:00) |
| If Melnyk loses court challenge to board, he'll start a new company. |
| |
|
Biovial Goes On, Melnyk Goes Away (25 June 08:13) |
| The biotech company may finally get back to work as a decision is announced. |
| |
|
Biovail Founder Melnyk Keeps Fighting (25 June 08:13) |
| The biotech company may finally get back to work as a decision is announced. |
| |
|
Barr Births A Deal With Bayer (24 June 11:19) |
| The generic maker got a break from the brand. |
| |
|
A Barr Beyond Bayer (24 June 11:19) |
| The generic maker got a break from the brand. |
| |
|
Bad Economy Gives Botox A Lift (24 June 07:33) |
| Demand for the injectible cosmetic drug rises. Doctors may have the downturn to thank. |
| |
|
ImmunoGen Snapped Up By Ziff (24 June 12:30) |
| Family investment concern takes above-market stake in cancer fighter. |
| |
|
Ziffs See Promise In ImmunoGen (24 June 12:30) |
| Family investment concern takes above-market stake in cancer fighter. |
| |
|
Sponsor's Content: Virtual Teams Get Closer (23 June 01:18) |
| Virtual teams are having cultural issues. But new team-building methods can help. |
| |
|
Pfizer Eyes New Use For Stem Cells (21 June 11:32) |
| Investment in biotech firm could lead to innovative treatment for diabetes-linked blindness. |
| |
|
Is Merck Flying Blind? (20 June 11:22) |
| The FDA delays a new heart drug by as much as five years. The question is why Merck didn't see it coming. |
| |
|
Biogen Says Icahn Can't Choose Its Board (20 June 01:58) |
| The biotech company chose not to rubber-stamp the billionaire's board choices. |
| |
|
Blackstone Warms The Hearth With Apria (19 June 11:33) |
| The home healthcare company has a valuable partnership in the works. |
| |
|
Apria Finds Solace With Blackstone (19 June 11:33) |
| The home healthcare company has a valuable partnership in the works. |
| |
|
The Battle For Biovail Continues (19 June 09:23) |
| A proxy fight continues between the pharmaceutical company and its shareholders. |
| |
|
Biovail Battered By In-Fighting (19 June 09:23) |
| A proxy fight continues between the pharmaceutical company and its shareholders. |
| |
|
Pfizer Wins Longer Life For Lipitor (18 June 11:51) |
| Drug giant cuts deal with Ranbaxy to keep generic version off market for five months, allowing billions in additional sale. |
| |
|
Alzheimer's Drug Trial Helps Investors Forget Wyeth Troubles (18 June 10:40) |
| Pharmaceutical company impresses with clinical data for candidate treatment. |
| |
|
Hope And Doubt For Alzheimer's (17 June 12:20) |
| A trial of the most-watched drug in biotech, from Elan and Wyeth, yields mixed results. |
| |
|
Cyberonics Hits New Highs, Continues Search (17 June 01:42) |
| Earnings and sales were up for the medical device maker. |
| |
|
Sponsor's Content: Fill the Tech Gap (16 June 01:25) |
| When it comes to technological generations, differences can draw companies together. |
| |
|
California Orders Stop To Gene Testing (14 June 07:30) |
| California follows New York State in telling gene testing companies to stop until they show they have clinical usefulness. |
| |
|
Sponsor's Content: Marketing ROI? Prove it. (14 June 07:17) |
| Show the bang of your marketing bucks with new BI tools. |
| |
|
Cordis Turnover Indicator of Stent Collapse (14 June 12:14) |
| A flurry of turnover at a stent maker shows further signs of weakness inthe industry. |
| |
|
Dented Stent Market Drives Cordis Turnovers (14 June 12:14) |
| A flurry of turnover at a stent maker shows further signs of weakness inthe industry. |
| |
|
Biovail Battle Bubbles Up (11 June 01:55) |
| The fight continues between the company and its largest shareholder. |
| |
|
Amylin Mum On Diabetes Drug Timetalble (11 June 12:40) |
| Company presents positive results on Byetta but doesn't say when it will file for approval. |
| |
|
ADA Hearts Amylin (11 June 12:40) |
| Company presents positive results on Byetta but doesn't say when it will file for approval. |
| |
|
Amylin Aims High With Byetta LAR (10 June 09:26) |
| Tha pharma company presents further data at the ADA meeting. |
| |
|
Novo Nordisk Drug Overshadows Amylin (09 June 11:55) |
| Danish drugmaker's diabetes treatment has shown stronger results in a study than the current market leader. |
| |
|
Nove Nordisk, Amylin Battle For Diabetes Market (09 June 11:55) |
| Danish drugmaker's diabetes treatment has shown stronger results in a study than the current market leader. |
| |
|
Better Byetta Drags On Amylin (09 June 10:45) |
| NovoNordisk's diabetes drug has shown stronger results in a study than the current market leader. |
| |
|
Sponsor's Content: Proving Your Marketing ROI (09 June 03:19) |
| Now because easy-to-use business intelligence tools provide clearer data, proving ROI for marketing dollars is within reach of just about anyone. |
| |
|
Sangamo Sinks On Interim Data (06 June 09:58) |
| Investors were not impressed with the biopharma company. |
| |
|
Sangamo Leaves Investors Guessing (06 June 03:58) |
| The biopharma company dropped 14.4%, following confusing results in its latest diabetes clinical trials. |
| |
|
Not So Sweet (06 June 03:30) |
| A pair of diabetes studies could raise big questions about how drugs are developed. |
| |
|
The French Invade U.S. Pharma (06 June 01:20) |
| Part-parent offers to buy in hormone specialist at a hefty premium. |
| |
|
Ipsen Bids For Tercica With Diminished Dollars (06 June 01:20) |
| Part-parent offers to buy in hormone specialist at a hefty premium. |
| |
|
Vertex Gambles On Telaprevir (05 June 11:05) |
| The biotech company sold off royalties to pay for human testing. |
| |
|
Vertex Throws Its Weight At Hep C (05 June 11:05) |
| The biotech company sold off royalties to pay for human testing. |
| |
|
France's Ipsen Woos Tercica (05 June 09:21) |
| Another foreign pharma company acquires a U.S. biotech. |
| |
|
Arthritis Drugs Cause Concern (05 June 02:45) |
| U.S. FDA examining treatments that might cause cancer in children. |
| |
|
Novartis Ups Fight Vs. Drug-Resistant Infections (05 June 01:11) |
| The Swiss-based pharma company expands its portfolio of biotechs. |
|
